348 related articles for article (PubMed ID: 20442215)
1. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
[TBL] [Abstract][Full Text] [Related]
2. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
[TBL] [Abstract][Full Text] [Related]
3. Interval lung cancers not detected on screening chest X-rays: How are they different?
Kvale PA; Johnson CC; Tammemägi M; Marcus PM; Zylak CJ; Spizarny DL; Hocking W; Oken M; Commins J; Ragard L; Hu P; Berg C; Prorok P
Lung Cancer; 2014 Oct; 86(1):41-6. PubMed ID: 25123333
[TBL] [Abstract][Full Text] [Related]
4. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
7. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
[TBL] [Abstract][Full Text] [Related]
8. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
[TBL] [Abstract][Full Text] [Related]
9. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
10. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
11. The impact of PLCO control arm contamination on perceived PSA screening efficacy.
Gulati R; Tsodikov A; Wever EM; Mariotto AB; Heijnsdijk EA; Katcher J; de Koning HJ; Etzioni R
Cancer Causes Control; 2012 Jun; 23(6):827-35. PubMed ID: 22488488
[TBL] [Abstract][Full Text] [Related]
12. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
Oken MM; Hocking WG; Kvale PA; Andriole GL; Buys SS; Church TR; Crawford ED; Fouad MN; Isaacs C; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Rathmell JM; Riley TL; Wright P; Caparaso N; Hu P; Izmirlian G; Pinsky PF; Prorok PC; Kramer BS; Miller AB; Gohagan JK; Berg CD;
JAMA; 2011 Nov; 306(17):1865-73. PubMed ID: 22031728
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
14. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
[TBL] [Abstract][Full Text] [Related]
15. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.
Gohagan J; Marcus P; Fagerstrom R; Pinsky P; Kramer B; Prorok P;
Chest; 2004 Jul; 126(1):114-21. PubMed ID: 15249451
[TBL] [Abstract][Full Text] [Related]
16. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
17. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
18. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]